Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes

Cancer - Tập 119 Số 23 - Trang 4094-4102 - 2013
Kosuke Okuwaki1, Mitsuhiro Kida1, Tetsuo Mikami2, Hiroshi Yamauchi1, Hiroshi Imaizumi1, Shiro Miyazawa1, Tomohisa Iwai1, Miyoko Takezawa1, Makoto Saegusa2, Masahiko Watanabe3, Wasaburo Koizumi1
1Department of Gastroenterology, Kitasato University East Hospital, Kanagawa, Japan
2Department of Pathology Kitasato University East Hospital Kanagawa Japan
3Department of Surgery, Kitasato University East Hospital, Kanagawa, Japan

Tóm tắt

BACKGROUNDThe impact of somatostatin receptor type 2 (SSTR‐2a) expression levels on outcomes in patients with pancreatic neuroendocrine tumors (PNETs) has not been evaluated.METHODSCorrelations between clinicopathologic characteristics, including SSTR‐2a expression and outcomes, were retrospectively studied in 79 patients with pancreatic neuroendocrine tumors (PNETs).RESULTSThe SSTR‐2a score was 0 in 27% of patients, 1 in 24% of patients, 3 in 30% of patients, and 4 in 18% of patients. The overall survival rate was 87% at 1 year, 77% at 3 years, and 71% at 5 years. On univariate analysis, a pancreatic tumor that measured ≥20 mm in greatest dimension, stage IV disease, vascular invasion, neuroendocrine carcinoma (NEC), and an SSTR‐2a score of 0 were associated significantly with poor outcomes. On multivariate analysis, NEC (P = .000; hazard ratio, 28.8; 95% confidence interval, 7.502‐111.240) and an SSTR‐2a score of 0 (P = .001; hazard ratio, 3.611; 95% confidence interval, 1.344‐9.702) were related independently to poor outcomes.CONCLUSIONSThe current analysis of prognostic factors in patients with PNETs demonstrated that NEC and an SSTR‐2a score of 0 both were significant independent predictors of poor outcomes. The results suggest that the assessment of SSTR‐2a may facilitate the selection of treatment regimens and the prediction of outcomes. Because a considerable proportion of patients with NEC have SSTR‐2a‐positive tumors, further analyses of the usefulness of somatostatin analogues are warranted in patients who have SSTR‐2a‐positive NEC. Cancer 2013. © 2013 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.1267/ahc.12006

10.1111/j.1572-0241.2000.03210.x

10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4

10.1530/eje.0.1460707

Sobin LH, 2009, International Union Against Cancer (UICC): TNM Classification of Malignant Tumours

Bosman FT, 2010, World Health Organization Classification of Tumours of the Digestive System

10.1038/modpathol.3800954

10.1159/000167796

10.1126/science.179.4068.77

10.1016/S0005-2736(03)00235-9

10.1053/j.gastro.2010.07.002

10.1073/pnas.92.5.1580

10.1007/s11102-006-0271-4

Jann H, 2012, Impact of octreotide LAR on tumour growth control as first‐line treatment in neuroendocrine tumours of pancreatic origin, Neuroendocrinology., 95, 157

10.1159/000330616

10.1016/j.surg.2012.02.011

10.1007/s00535-009-0194-8

10.1056/NEJMoa1003825

10.1056/NEJMoa1009290

10.1007/s10620-006-8001-3

10.1159/000338794

Wildemberg LE, 2012, Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT‐PCR and immunohistochemistry, J Endocrinol Invest., 35, 580

Thông tin
Thông tin xuất bản

Cancer

Tập 119 Số 23

4094-4102

Thông tin tác giả